In conclusion, this study suggested that the expressions of S100A6, S100A10, S100A16, and SDC1 were upregulated in PAAD, which might be crucial biomarkers in the progression of PAAD. The gene discussed is S100A16; the disease is pancreatic adenocarcinoma.